An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a zoster vaccine (live), Zostavax, in subjects greater than or equal to 70 years of age.
Phase of Trial: Phase III
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics
- Sponsors sanofi pasteur MSD
- 23 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jul 2008 The expected completion date for this trial is now 1 Sep 2009.
- 04 Jul 2008 Status changed from recruiting to in progress.